OUR MISSION:
Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.
These are our Core Values:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
PROJECT InterGR
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. Project InterGR, the LRG’s approach to research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Information.
Join The Life Raft Group.
Available GIST clinical trials.
Search our database of GIST Specialists.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Marc Wasserman
Diagnosed in 2006 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-Deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help, we always need patient tissue and data in our registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
First-Line Imatinib More Effective Than Widely Believed – LRG Science
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
First-Line Imatinib More Effective Than Widely Believed – LRG Science
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Medicamentos Para GIST: Existentes y Nuevos
Esta presentación cuenta la historia de los medicamentos para GIST, de cómo llagamos a donde hoy estamos, y como miramos hacia [...]
Current and Emerging Medications For GIST
Pete Knox's presentation on current and emerging medications for GIST.
